BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22660807)

  • 1. Patient-acceptable symptom state as an outcome measure in the daily care of patients with ankylosing spondylitis.
    Rodríguez-Lozano C; Gantes MÁ; González B; Hernández-Beriain JA; Naranjo A; Hernández V; Quevedo-Abeledo JC; Falcón MJ; Machín S; Descalzo MA
    J Rheumatol; 2012 Jul; 39(7):1424-32. PubMed ID: 22660807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis.
    Maksymowych WP; Richardson R; Mallon C; van der Heijde D; Boonen A
    Arthritis Rheum; 2007 Feb; 57(1):133-9. PubMed ID: 17266072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis.
    Tubach F; Pham T; Skomsvoll JF; Mikkelsen K; Bjørneboe O; Ravaud P; Dougados M; Kvien TK
    Arthritis Rheum; 2006 Dec; 55(6):960-3. PubMed ID: 17139643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study.
    Tubach F; Ravaud P; Martin-Mola E; Awada H; Bellamy N; Bombardier C; Felson DT; Hajjaj-Hassouni N; Hochberg M; Logeart I; Matucci-Cerinic M; van de Laar M; van der Heijde D; Dougados M
    Arthritis Care Res (Hoboken); 2012 Nov; 64(11):1699-707. PubMed ID: 22674853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thresholds of patient-reported outcomes that define the patient acceptable symptom state in ankylosing spondylitis vary over time and by treatment and patient characteristics.
    Maksymowych WP; Gooch K; Dougados M; Wong RL; Chen N; Kupper H; van der Heijde D
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):826-34. PubMed ID: 20535793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
    van der Heijde D; Lie E; Kvien TK; Sieper J; Van den Bosch F; Listing J; Braun J; Landewé R;
    Ann Rheum Dis; 2009 Dec; 68(12):1811-8. PubMed ID: 19060001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Kvamme MK; Kristiansen IS; Lie E; Kvien TK
    J Rheumatol; 2010 Jan; 37(1):26-31. PubMed ID: 19955045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of spondylarthritis activity by patients and physicians: ASDAS, BASDAI, PASS, and flares in 200 patients.
    Godfrin-Valnet M; Prati C; Puyraveau M; Toussirot E; Letho-Gyselink H; Wendling D
    Joint Bone Spine; 2013 Jul; 80(4):393-8. PubMed ID: 23453478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of the ASDAS index in comparison with BASDAI in patients with ankylosing spondylitis (Axis Study).
    Sellas I Fernandez A; Juanola Roura X; Alonso Ruiz A; Rosas J; Medina Luezas J; Collantes Estevez E; Abad Hernández MÁ; Carrasco Benitez V; Fisac C
    Rheumatol Int; 2017 Nov; 37(11):1817-1823. PubMed ID: 28918450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.
    Lukas C; Landewé R; Sieper J; Dougados M; Davis J; Braun J; van der Linden S; van der Heijde D;
    Ann Rheum Dis; 2009 Jan; 68(1):18-24. PubMed ID: 18625618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis.
    Kviatkovsky MJ; Ramiro S; Landewé R; Dougados M; Tubach F; Bellamy N; Hochberg M; Ravaud P; Martin-Mola E; Awada H; Bombardier C; Felson D; Hajjaj-Hassouni N; Logeart I; Matucci-Cerinic M; van de Laar M; van der Heijde D
    J Rheumatol; 2016 Sep; 43(9):1680-6. PubMed ID: 27307522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial.
    Dougados M; Luo MP; Maksymowych WP; Chmiel JJ; Chen N; Wong RL; Davis JC; van der Heijde D;
    Arthritis Rheum; 2008 Apr; 59(4):553-60. PubMed ID: 18383418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validity of the ankylosing spondylitis disease activity score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme.
    Fernández-Espartero C; de Miguel E; Loza E; Tomero E; Gobbo M; Descalzo MA; Collantes-Estévez E; Mulero J; Muñoz-Fernández S; Zarco P; Carmona L;
    Ann Rheum Dis; 2014 Jul; 73(7):1350-5. PubMed ID: 23709245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria.
    Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Kaufmann C; Rødevand E; Mikkelsen K; Kalstad S; Kvien TK
    Rheumatology (Oxford); 2012 Aug; 51(8):1479-83. PubMed ID: 22499062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors.
    Pedersen SJ; Sørensen IJ; Garnero P; Johansen JS; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Lambert R; Hansen A; Østergaard M
    Ann Rheum Dis; 2011 Aug; 70(8):1375-81. PubMed ID: 21551511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The value of ankylosing spondylitis disease activity score in evaluating disease activity of ankylosing spondylitis].
    DU XN; Li Y; Zhang SL; Zhu J; Huang F
    Zhonghua Nei Ke Za Zhi; 2012 Mar; 51(3):206-9. PubMed ID: 22781894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatigue in patients with ankylosing spondylitis: A comparison with the general population and associations with clinical and self-reported measures.
    Dagfinrud H; Vollestad NK; Loge JH; Kvien TK; Mengshoel AM
    Arthritis Rheum; 2005 Feb; 53(1):5-11. PubMed ID: 15696569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study.
    Pavy S; Brophy S; Calin A
    J Rheumatol; 2005 Jan; 32(1):80-5. PubMed ID: 15630730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parent and child acceptable symptom state in juvenile idiopathic arthritis.
    Filocamo G; Consolaro A; Schiappapietra B; Ruperto N; Pistorio A; Solari N; Pederzoli S; Verazza S; Martini A; Ravelli A
    J Rheumatol; 2012 Apr; 39(4):856-63. PubMed ID: 22298905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.